Fortress Biotech’s (FBIO) Buy Rating Reiterated at Roth Mkm
Fortress Biotech (NASDAQ:FBIO – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at Roth Mkm in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $15.00. Other research analysts have […]
Fortress Biotech (NASDAQ:FBIO – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at Roth Mkm in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $15.00. Other research analysts have […]
